(Q42555782)

2 November 2017

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir (English)

1 reference

2 November 2017

1 reference

Molla A

1

1 reference

2 November 2017

Korneyeva M

2

1 reference

2 November 2017

Gao Q

3

1 reference

2 November 2017

Vasavanonda S

4

1 reference

2 November 2017

Schipper PJ

5

1 reference

2 November 2017

Mo HM

6

1 reference

2 November 2017

Markowitz M

7

1 reference

2 November 2017

Chernyavskiy T

8

1 reference

2 November 2017

Niu P

9

1 reference

2 November 2017

Lyons N

10

1 reference

2 November 2017

Hsu A

11

1 reference

2 November 2017

Granneman GR

12

1 reference

2 November 2017

Ho DD

13

1 reference

2 November 2017

Boucher CA

14

1 reference

2 November 2017

Leonard JM

15

1 reference

2 November 2017

Norbeck DW

16

1 reference

2 November 2017

Kempf DJ

17

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 July 1996

1 reference

2 November 2017

1 reference

2 November 2017

2

1 reference

2 November 2017

760-766

1 reference

2 November 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nm0796-760

2 November 2017

0 references

cites work

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

Safety and activity of saquinavir in HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0796-760

7 January 2021

Identifiers

DOI

10.1038/NM0796-760

1 reference

2 November 2017

1 reference